Genocea Biosciences Inc (GNCAQ)
0.00
USD |
OTCM |
May 13, 16:00
Genocea Biosciences PS Ratio
PS Ratio Chart
Historical PS Ratio Data
| Date | Value |
|---|---|
| June 29, 2016 | 150.91 |
| June 28, 2016 | 150.57 |
| June 27, 2016 | 131.79 |
| June 24, 2016 | 143.23 |
| June 23, 2016 | 159.45 |
| June 22, 2016 | 125.99 |
| June 21, 2016 | 126.67 |
| June 20, 2016 | 127.35 |
| June 17, 2016 | 126.67 |
| June 16, 2016 | 133.16 |
| June 15, 2016 | 136.91 |
| June 14, 2016 | 133.50 |
| June 13, 2016 | 131.79 |
| June 10, 2016 | 134.52 |
| June 09, 2016 | 144.08 |
| June 08, 2016 | 152.28 |
| June 07, 2016 | 158.42 |
| June 06, 2016 | 162.18 |
| June 03, 2016 | 160.81 |
| June 02, 2016 | 171.06 |
| June 01, 2016 | 161.50 |
| May 31, 2016 | 160.47 |
| May 27, 2016 | 135.89 |
| May 26, 2016 | 132.13 |
| May 25, 2016 | 138.96 |
| Date | Value |
|---|---|
| May 24, 2016 | 137.60 |
| May 23, 2016 | 135.21 |
| May 20, 2016 | 136.91 |
| May 19, 2016 | 122.91 |
| May 18, 2016 | 129.06 |
| May 17, 2016 | 135.55 |
| May 16, 2016 | 123.26 |
| May 13, 2016 | 117.11 |
| May 12, 2016 | 117.11 |
| May 11, 2016 | 125.99 |
| May 10, 2016 | 130.77 |
| May 09, 2016 | 133.16 |
| May 06, 2016 | 125.30 |
| May 05, 2016 | 132.47 |
| May 04, 2016 | 138.28 |
| May 03, 2016 | 133.50 |
| May 02, 2016 | 145.79 |
| April 29, 2016 | 150.23 |
| April 28, 2016 | 157.06 |
| April 27, 2016 | 171.06 |
| April 26, 2016 | 165.25 |
| April 25, 2016 | 177.54 |
| April 22, 2016 | 187.79 |
| April 21, 2016 | 182.66 |
| April 20, 2016 | 176.86 |
Price to Sales Ratio Definition
The Price to Sales Ratio (PS Ratio) is calculated by taking the stock price / revenue per share (ttm). This metric is considered a valuation metric that confirms whether the sales of a company justifies the stock price. There isn't necesarily an optimum PS ratio, since different industries will have different ranges of PS Ratios. Because of this, PS Ratio is great to evaluate from a relative standpoint with other similar companies. PS Ratio might also be a handy metric for companies that are not profitable yet, since they might be valued moreso by their overall sales and potential of becoming profitable in the future.
PS Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
PS Ratio Benchmarks
| NovaBay Pharmaceuticals Inc | 0.029 |
| Palatin Technologies Inc | 4.230 |
| iBio Inc | -- |
| Theriva Biologics Inc | -- |
| Oragenics Inc | 3.098 |